Silkit Pharma

Silkit was an Israel-based biotechnology company focused on developing a proprietary platform for the sustained release of drugs and biologicals using silk proteins. The company's primary focus was on ophthalmic applications, specifically creating long-acting injectable or implantable formulations for the treatment of glaucoma and ocular hypertension. By leveraging the unique biocompatibility and mechanical properties of silk fibroin, Silkit aimed to reduce the frequency of administration and improve patient compliance compared to traditional daily eye drops. The company operated as a portfolio company within the Trendlines Medical incubator but is currently listed as closed.